Literature DB >> 16618894

Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells.

Abby L Mulkeen1, Teresa Silva, Peter S Yoo, John C Schmitz, Edward Uchio, Edward Chu, Charles Cha.   

Abstract

HYPOTHESIS: By using short interfering RNA (siRNA) to inhibit the in vitro expression of vascular endothelial growth factor (VEGF) A, we hope to further investigate the presence of an autocrine loop in colon cancer cells. We hypothesize that VEGF inhibition will result in decreased cellular proliferation.
DESIGN: Human colon cancer cells were evaluated for the expression of VEGF and VEGF receptor 2 (VEGFR-2). In vitro assessments were then made of the ability of anti-VEGF siRNA to knock down expression of VEGF and the subsequent effect this decreased expression had on colon cancer cell proliferation.
SETTING: Surgical oncology research laboratory.
INTERVENTIONS: Human colon cancer cells from the RKO cell line were transfected with siRNA targeting the coding region of VEGF. MAIN OUTCOME MEASURES: Enzyme-linked immunosorbent assay, Northern blot analysis, and real-time quantitative polymerase chain reaction were performed to establish the ability of siRNA to decrease VEGF production. Proliferation assays were run on transfected and wild-type cells to establish concomitant decrease in VEGF expression and cellular proliferation.
RESULTS: The RKO colon cancer cells expressed both VEGF and VEGFR-2. Those cells transfected with siRNA targeting VEGF showed a 94% knockdown in VEGF expression and a 67% decrease in cellular proliferation.
CONCLUSION: Colon cancer cells expressing VEGF and VEGFR-2 may possess an autocrine growth pathway that can be effectively targeted using RNA interference as an antiangiogenic therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618894     DOI: 10.1001/archsurg.141.4.367

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  10 in total

1.  Suppression of vascular endothelial growth factor via siRNA interference modulates the biological behavior of human nasopharyngeal carcinoma cells.

Authors:  Hai B Zhou; Yi F Yin; Yan Hu; Xin Li; Li Y Zou; Yong J Li; Yu Gu; Bao Q Ou; Juan Fu; Jun H Du; Gang Wu
Journal:  Jpn J Radiol       Date:  2011-09-29       Impact factor: 2.374

2.  RNA interference-mediated gene silencing of vascular endothelial growth factor in colon cancer cells.

Authors:  Tie-Jun Li; Jian-Ning Song; Kai Kang; Shu-Sheng Tong; Zan-Lan Hu; Tong-Chuan He; Bing-Qiang Zhang; Cai-Quan Zhang
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

Review 3.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

4.  Protein kinase Cbeta is an effective target for chemoprevention of colon cancer.

Authors:  Alan P Fields; Shelly R Calcagno; Murli Krishna; Sofija Rak; Michael Leitges; Nicole R Murray
Journal:  Cancer Res       Date:  2009-02-15       Impact factor: 12.701

5.  1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis.

Authors:  Miroslaw Kornek; Veronika Lukacs-Kornek; Andreas Limmer; Esther Raskopf; Ursula Becker; Maren Klöckner; Tilman Sauerbruch; Volker Schmitz
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

6.  Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.

Authors:  Jonah D Klein; Apostolos Christopoulos; Sun M Ahn; William E Gooding; Jennifer R Grandis; Seungwon Kim
Journal:  Head Neck       Date:  2012-02-06       Impact factor: 3.147

7.  VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.

Authors:  A H R Varey; E S Rennel; Y Qiu; H S Bevan; R M Perrin; S Raffy; A R Dixon; C Paraskeva; O Zaccheo; A B Hassan; S J Harper; D O Bates
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

8.  miR-29a suppresses growth and invasion of gastric cancer cells in vitro by targeting VEGF-A.

Authors:  Ling Chen; Hong Xiao; Zong-Hua Wang; Yi Huang; Zi-Peng Liu; Hui Ren; Hang Song
Journal:  BMB Rep       Date:  2014-01       Impact factor: 4.778

9.  The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A.

Authors:  Ranran Kong; Yuefeng Ma; Jie Feng; Shaomin Li; Wei Zhang; Jiantao Jiang; Jin Zhang; Zhe Qiao; Xiaoping Yang; Bin Zhou
Journal:  Cell Mol Biol Lett       Date:  2016-07-28       Impact factor: 5.787

10.  Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor.

Authors:  Paul Mésange; Virginie Poindessous; Michèle Sabbah; Alexandre E Escargueil; Aimery de Gramont; Annette K Larsen
Journal:  Oncotarget       Date:  2014-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.